NEW YORK (Reuters) - Actavis Plc plans to make a new approach for Allergan Inc about a potential merger, as the Botox maker warms up to the possibility of a sale, said people familiar with the matter. Allergan, which has repeatedly rejected approaches from Valeant Pharmaceuticals International Inc , would consider a takeover proposal that values the company at above $200 per share, these people said. ...
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment